Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inactive tyrosine-protein phosphatase STYX (STYX) is a catalytically inactive member of the dual-specificity phosphatase family structurally similar to protein tyrosine phosphatases but lacking a critical active-site cysteine, rendering it enzymatically inactive[1][2][4]. Instead of dephosphorylation, STYX functions mainly by binding to phosphorylated proteins—serving as a nuclear anchor for ERK1/2 and regulating the duration and localization of ERK signaling[1]. This role modulates processes such as Golgi polarization, cell migration, and differentiation, with implications for the invasive and metastatic potential of cancer cells[1][2]. In various cell types, including cancer cells, STYX is involved in stress response modulation by inhibiting the assembly of stress granules through protein–protein interactions rather than direct enzymatic action[3]. STYX is upregulated in several cancers and acts as a potential oncogene, indicating promise as a diagnostic or prognostic biomarker and a candidate therapeutic target[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inactive tyrosine-protein phosphatase STYX (STYX).